Home/Pipeline/Novel Chemical Entity - Oncology

Novel Chemical Entity - Oncology

Solid Tumors

Phase IActive (Internal Discovery)

Key Facts

Indication

Solid Tumors

Phase

Phase I

Status

Active (Internal Discovery)

Company

Guangzhou Baiyunshan Pharmaceutical Holdings

About Guangzhou Baiyunshan Pharmaceutical Holdings

Baiyunshan's mission is to leverage its dual heritage in Traditional Chinese Medicine and modern pharmaceuticals to become a global leader in integrated healthcare. Its key achievements include establishing one of China's most recognized pharmaceutical brands, building a diversified portfolio with numerous blockbuster TCM formulas and generic drugs, and operating a massive, vertically integrated supply chain. The company's strategy focuses on deepening its TCM scientific validation, expanding its innovative and generic chemical drug pipeline, and capitalizing on supportive national healthcare policies to drive sustainable growth.

View full company profile

Therapeutic Areas

Oncology Cardiovascular & Metabolic Respiratory Anti-infective Neurological/CNS General Health & Wellness

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active